UNION CITY, Calif.,
Feb. 22, 2011 /PRNewswire/ -- Abaxis,
Inc. (Nasdaq: ABAX), a medical products company manufacturing
point-of-care blood analysis systems, announced today that
Clint Severson, chairman and chief
executive officer, will present at the Citi 2011 Global Health Care
Conference on Wednesday, March 2,
2011 at 1:30 p.m. ET. The
conference will be held at the Hilton New York Hotel in
New York City.
About Abaxis
Abaxis develops, manufactures and markets portable blood
analysis systems for use in any veterinary or human patient-care
setting to provide clinicians with rapid blood constituent
measurements. The system consists of a compact, 5.1 kilogram (11.2
pounds), portable analyzer and a series of single-use plastic
discs, called reagent discs that contain all the chemicals required
to perform a panel of up to 13 tests on veterinary patients and 14
tests on human patients. The system can be operated with minimal
training and performs multiple routine tests on whole blood, serum
or plasma samples. The system provides test results in less than 12
minutes with the precision and accuracy equivalent to a clinical
laboratory analyzer.
The audio webcast available to Citi's institutional clients
will include, statements that constitute "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 (the "Reform Act"), including but not limited to
statements related to Abaxis' cash position, financial resources
and potential for future growth, market acceptance and penetration
of new or planned product offerings, and future recurring revenues
and results of operations. Abaxis claims the protection of
the safe-harbor for forward-looking statements contained in the
Reform Act. These forward-looking statements are often
characterized by the terms "may," "believes," "projects,"
"expects," "anticipates," or words of similar import, and do not
reflect historical facts. Specific forward-looking statements
contained in this press release or in Abaxis' conference call may
be affected by risks and uncertainties, including, but not limited
to, those related to losses or system failures with respect to
Abaxis' facilities or manufacturing operations, fluctuations in
quarterly operating results, dependence on sole suppliers, the
market acceptance of Abaxis' products and the continuing
development of its products, required United States Food and Drug
Administration clearance and other government approvals, risks
associated with manufacturing and distributing its products on a
commercial scale free of defects, risks related to the introduction
of new instruments manufactured by third parties, risks associated
with competing in the human diagnostic market, risks related to the
protection of Abaxis' intellectual property or claims of
infringement of intellectual property asserted by third parties,
risks related to condition of the United
States economy and other risks detailed under "Risk Factors"
in Abaxis' Quarterly Report on Form 10-Q for the fiscal
quarter ended December 31, 2010
and Abaxis' other periodic reports filed from time to time with
the United States Securities and Exchange Commission.
Forward-looking statements speak only as of the date the
statements were made. Abaxis does not undertake and
specifically disclaims any obligation to update any forward-looking
statements.
Contact:
|
Clint Severson
|
Lytham Partners, LLC
|
|
|
Chief Executive
Officer
|
Joe Dorame, Joe Diaz &
Robert Blum
|
|
|
ABAXIS, Inc.
|
602-889-9700
|
|
|
510-675-6500
|
|
|
|
|
|
SOURCE Abaxis, Inc.